Spero Therapeutics (SPRO) Treasury Shares (2016 - 2017)

Spero Therapeutics' (SPRO) quarterly Treasury Shares came in at $43.3 million in Q3 2017, up 219.26% on a QoQ basis from $13.5 million in Q4 2016.

Spero Therapeutics (SPRO) Treasury Shares (2016 - 2017) Analysis & Trends

Spero Therapeutics (SPRO) has 2 years of Treasury Shares data on file, last reported at $43.3 million in Q3 2017.

Quarterly Treasury Shares changed N/A year-over-year to $43.3 million in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $43.3 million (changed N/A YoY) and the FY2016 annual result came in at $13.5 million, up 77.34% from the prior year.
Treasury Shares rose to $43.3 million in Q3 2017, from $13.5 million in the prior quarter.
In the past five years, Treasury Shares ranged from a high of $43.3 million in Q3 2017 to a low of $13.5 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	138.81 Bn	130.96 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.07 Bn	78.08 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	65.47 Bn	60.29 Bn	1.37 Bn	-
4	Moderna	55.64 Bn	50.50 Bn	52.00 Mn	-
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.68 Bn	28.37 Bn	992.69 Mn	-
7	BioNTech SE	27.69 Bn	9.29 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
9	Royalty Pharma	27.36 Bn	26.52 Bn	-	2.72 Mn
10	Spero Therapeutics	70.72 Mn	19.95 Mn	-	-

Download Data